Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet
- Posted on August 26, 2026
- By Fortune
- 0 Views
- 1 min read
In brief
Generating AI summary…
Why Wall Street sees a $39,800 pancreatic cancer pill as proof of a much bigger bet
Dr. Danish Nagda, a shareholder in the developer, told Fortune it was "incredibly exciting ... maybe half a decade away from the post-cancer era."
)
